SHB.B

220.8

-0.54%↓

SWED.A

325.5

-1.39%↓

SCA.A

134.95

-0.59%↓

EVO

583.4

-0.82%↓

SKF.B

215

+0.23%↑

SHB.B

220.8

-0.54%↓

SWED.A

325.5

-1.39%↓

SCA.A

134.95

-0.59%↓

EVO

583.4

-0.82%↓

SKF.B

215

+0.23%↑

SHB.B

220.8

-0.54%↓

SWED.A

325.5

-1.39%↓

SCA.A

134.95

-0.59%↓

EVO

583.4

-0.82%↓

SKF.B

215

+0.23%↑

SHB.B

220.8

-0.54%↓

SWED.A

325.5

-1.39%↓

SCA.A

134.95

-0.59%↓

EVO

583.4

-0.82%↓

SKF.B

215

+0.23%↑

SHB.B

220.8

-0.54%↓

SWED.A

325.5

-1.39%↓

SCA.A

134.95

-0.59%↓

EVO

583.4

-0.82%↓

SKF.B

215

+0.23%↑

Search

Ratos AB (Class B)

Открыт

33.18 -0.36

Обзор

Изменение цены акций

24 ч

Текущая

Мин.

32.72

Макс.

33.56

Ключевые показатели

By Trading Economics

Доход

-2.1B

-1.7B

Продажи

436M

4.6B

P/E

Средняя по отрасли

11.333

54.048

Прибыль на акцию

-5.32

Дивидендная доходность

3.87

Рентабельность продаж

-37.883

Сотрудники

8,591

EBITDA

-870M

136M

Дивиденды

By Dow Jones

Дивидендная доходность

Средняя по отрасли

3.87%

4.84%

Рыночная статистика

By TradingEconomics

Рыночная капитализация

17M

12B

Предыдущая цена открытия

33.54

Предыдущая цена закрытия

33.18

Ratos AB (Class B) График

Прошлые результаты не являются надежным индикатором будущих результатов.

Связанные новости

23 мар. 2026 г., 23:47 UTC

Приобретения, слияния, поглощения

Gilead Sciences to Buy Ouro Medicines, Collaborate With Galapagos on Purchased Assets -- Update

23 мар. 2026 г., 22:55 UTC

Приобретения, слияния, поглощения

Gilead Sciences to Buy Ouro Medicines for Up to $2.18 Billion

23 мар. 2026 г., 21:51 UTC

Приобретения, слияния, поглощения

Italy's Postal Service Makes $12.50 Billion Bid for Telecom Italia -- 3rd Update

23 мар. 2026 г., 23:59 UTC

Обсуждения рынка

Global Equities Roundup: Market Talk

23 мар. 2026 г., 23:59 UTC

Обсуждения рынка

Woodside, Santos Earnings Power Up on Surging LNG Prices -- Market Talk

23 мар. 2026 г., 23:50 UTC

Обсуждения рынка

Nikkei May Rise on Hopes for U.S. Talks With Iran -- Market Talk

23 мар. 2026 г., 23:37 UTC

Обсуждения рынка

Gold Rises, Boosted by Fall in Dollar, U.S. Treasury Yields -- Market Talk

23 мар. 2026 г., 22:42 UTC

Обсуждения рынка
Главные новостные события

Global Equities Roundup: Market Talk

23 мар. 2026 г., 22:42 UTC

Обсуждения рынка
Главные новостные события

Bell Potter Names Miners Less Exposed to Fuel Price, Supply Risks -- Market Talk

23 мар. 2026 г., 22:40 UTC

Приобретения, слияния, поглощения

Gilead Sciences to Buy Ouro Medicines for Up to $2.18B

23 мар. 2026 г., 22:23 UTC

Обсуждения рынка

Apollo Debt Solutions Shrugs Off Private-Credit Fears -- Market Talk

23 мар. 2026 г., 22:22 UTC

Приобретения, слияния, поглощения

Gilead Sciences: OM336 Is for Treatment of Autoantibodies Driven Immune-Mediated Disease

23 мар. 2026 г., 22:21 UTC

Приобретения, слияния, поглощения

Gilead Sciences: Company Would Pay Galapagos Royalties of 20%-23% of Net OM336 Sales

23 мар. 2026 г., 22:21 UTC

Приобретения, слияния, поглощения

Gilead Sciences: Company Would Retain Sole Worldwide Commercialization Rights of OM336 Outside of Greater China

23 мар. 2026 г., 22:20 UTC

Приобретения, слияния, поглощения

Gilead Sciences: Company, Galapagos Would Collaborate on Development of OM336 >GILD

23 мар. 2026 г., 22:20 UTC

Приобретения, слияния, поглощения

Gilead Sciences: Galapagos Would Absorb Substantially All of Ouro's Operating Assets, Retain Its Employees >GILD

23 мар. 2026 г., 22:19 UTC

Приобретения, слияния, поглощения

Gilead Sciences: Galapagos Would Pay 50% of Upfront Consideration and 50% of Any Contingent Milestone Payments Payable to Ouro Shareholders

23 мар. 2026 г., 22:19 UTC

Приобретения, слияния, поглощения

Gilead Sciences: Currently in Advanced Discussions With Galapagos With Respect to Potential Research-and-Development Collaboration on Acquired Ouro Assets

23 мар. 2026 г., 22:18 UTC

Приобретения, слияния, поглощения

Gilead Sciences to Buy Ouro Medicines for About $1.68B Upfront, Up to $500M in Contingent Milestone Payments >GILD

23 мар. 2026 г., 22:15 UTC

Приобретения, слияния, поглощения

Gilead Sciences To Acquire Ouro Medicines To Advance First In Class T Cell Engager Program For Autoimmune Diseases >GILD

23 мар. 2026 г., 22:08 UTC

Обсуждения рынка

Ebos Needs to Reset Its Gearing Targets -- Market Talk

23 мар. 2026 г., 21:42 UTC

Обсуждения рынка

Global Forex and Fixed Income Roundup: Market Talk

23 мар. 2026 г., 21:42 UTC

Обсуждения рынка

RBNZ's Breman Strikes Reassuring Tone On Rates -- Market Talk

23 мар. 2026 г., 21:32 UTC

Отчет

WuXi XDC Cayman: Results Aided by Strong Growth in Contract Research, Development and Manufacturing Organisation Business>2268.HK

23 мар. 2026 г., 21:32 UTC

Отчет

WuXi XDC Cayman 2025 Net CNY1.56B Vs. Net CNY917.16M >2268.HK

23 мар. 2026 г., 21:32 UTC

Отчет

WuXi XDC Cayman 2025 Rev CNY5.94B Vs. CNY4.05B >2268.HK

23 мар. 2026 г., 21:10 UTC

Главные новостные события

Oil Is Back Under $100. Trump Says Iran Has Agreed to No Nuclear Weapons. -- Barrons.com

23 мар. 2026 г., 20:50 UTC

Обсуждения рынка

Tech, Media & Telecom Roundup: Market Talk

23 мар. 2026 г., 20:50 UTC

Обсуждения рынка

Health Care Roundup: Market Talk

23 мар. 2026 г., 20:50 UTC

Обсуждения рынка
Отчет
Главные новостные события

Basic Materials Roundup: Market Talk

Сравнение c конкурентами

Изменение цены

Ratos AB (Class B) Прогноз

Финансовые показатели

Расходы на продажи и администрирование

Операционные расходы

Прибыль до уплаты налогов

Продажи

Себестоимость реализации

Валовая прибыль от продаж

Процентные расходы по долгу

EBITDA

Операционная прибыль

$

О компании Ratos AB (Class B)

Ratos AB (publ) is a private equity firm specializing in buyouts, turnarounds, add on acquisitions, and middle market transactions. The firm does not invest in early stages and in companies that operate in the arms industry, pornography, or are detrimental to the environment. It seeks to invest in unlisted medium sized companies. The firm invests in industry, construction and services, consumer, and technology sectors. The firm typically invests in the Nordic region, with focus on Sweden, Finland, Denmark, and Norway. It seeks to invest in companies with equity investments between SEK250 million ($23.57 million) and SEK5000 million ($471.57 million), sales value between SEK300 million ($28.29 million) and SEK5000 million ($471.57 million) and EBITDA greater than SEK50 million ($4.71 million). The firm takes both minority and majority stakes. The firm prefers to be the principal owner with a minimum holding of at least 20 percent and also seeks a board seat. It prefers to hold its investment between five to ten years. Ratos AB (publ) was founded in 1934 and is based in Stockholm, Sweden.
help-icon Live chat